Stock QURE UNIQURE N.V.
Add to a list
To use this feature you must be a member
Log inSign up

All News uniQure N.V.

Equities

QURE

NL0010696654

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-16 pm EDT 		5-day change 1st Jan Change
5.07 USD +0.20% Intraday chart for uniQure N.V. 0.00% -25.11%
May. 08 Mizuho Adjusts uniQure's Price Target to $6 From $7, Keeps Neutral Rating MT
May. 07 UniQure N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Mizuho Adjusts uniQure's Price Target to $6 From $7, Keeps Neutral Rating
MT
UniQure N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Earnings Flash (QURE) UNIQURE Reports Q1 Revenue $8.5M
MT
UniQure: Q1 Earnings Snapshot
AQ
UniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
GL
Uniqure N.V. Announces Paula Soteropoulos Will Not Stand for Re-Election as Non-Executive Director
CI
UBS Lowers UniQure's Price Target to $27 From $38, Maintains Buy Rating
MT
UniQure N.V.(NasdaqGS:QURE) dropped from S&P Biotechnology Select Industry Index
CI
Mizuho Securities Adjusts Price Target on uniQure to $7 From $10, Maintains Neutral Rating
MT
Goldman Sachs Downgrades UniQure to Neutral From Buy, Cuts Price Target to $8 From $63
MT
UniQure N.V. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
UniQure Announces 2023 Financial Results and Highlights Recent Company Progress
GL
RBC Cuts Price Target on UniQure to $28 From $33, Keeps Outperform Rating, Speculative Risk Qualifier
MT
Kempen Downgrades UniQure to Neutral From Buy, Cuts Price Target to $18 From $28
MT
Transcript : UniQure N.V. - Special Call
Mizuho Downgrades uniQure to Neutral From Buy, Cuts Price Target to $10 From $52
MT
UniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
GL
UniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
AQ
UniQure N.V. Announces Update on Phase I/II Clinical Trials of Amt-130Gene Therapy for the Treatment of Huntington's Disease
CI
UniQure N : December 2023 Huntington's Disease Program Update AMT-130
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. QURE Stock
  4. News uniQure N.V.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW